Note: This document contains side effect information about halobetasol / tazarotene topical. Some dosage forms listed on this page may not apply to the brand name Duobrii.
Applies to halobetasol/tazarotene topical: topical application lotion.
Serious side effects of Duobrii
Along with its needed effects, halobetasol/tazarotene topical may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking halobetasol / tazarotene topical:
More common
- Blistering, burning, crusting, drying, or flaking of the skin
- itching, scaling, severe redness, soreness, or swelling of the skin
Less common
- Breakdown, weakness, falling off, or wasting away of the skin
- burning, itching, and pain in hairy areas, pus at the root of the hair
- skin scrape or irritation
- thinning of skin with easy bruising, especially when used on the face or areas where the skin may touch or rub together
Other side effects of Duobrii
Some side effects of halobetasol / tazarotene topical may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Less common
- Pain at the application site
For Healthcare Professionals
Applies to halobetasol / tazarotene topical: topical lotion.
Local
Common (1% to 10%): Application site pain, folliculitis, skin atrophy, excoriation, rash, skin abrasion, skin exfoliation[Ref]
Ocular
Postmarketing reports: Cataracts, glaucoma[Ref]
Dermatologic
Common (1% to 10%): Contact dermatitis
Frequency not reported: Photosensitivity, sunburn[Ref]
Endocrine
Very common (10% or more): Hypothalamic-pituitary-adrenal (HPA) axis suppression (15%)[Ref]
